{
    "symbol": "NVO",
    "slug": "nvo",
    "display_name": "NVO",
    "category": "stocks",
    "region": "EU",
    "description": null,
    "url": "https://finscans.com/asset/nvo",
    "lang": "en",
    "as_of": "2026-05-22T14:38:57+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 1,
        "bearish": 0,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 8,
        "avg_confidence": 90,
        "last_signal_at": "2026-05-22 13:51:05",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "EMA CHMP positive opinion on Wegovy oral",
            "count": 1
        },
        {
            "text": "Potential European Commission approval within months",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Competition from Eli Lilly's orforglipron progressing in trials",
            "count": 1
        },
        {
            "text": "Pricing and reimbursement challenges in European markets",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-05-22 13:51:05",
            "sentiment": "Bullish",
            "impact_score": 8,
            "confidence_score": 90,
            "mention_type": "explicit",
            "timeframe": "mid-term",
            "region": "EU",
            "reasoning": "The EMA panel recommended approval of Novo Nordisk’s oral Wegovy, a key regulatory milestone that expands the company’s obesity franchise into non-injectable treatment in Europe. The recommendation validates semaglutide’s oral formulation and positions Novo to capture a broader patient base, supporting revenue growth projections. Peak sales estimates for the oral pill exceed $10 billion, and the shares rallied premarket on the news.",
            "article": {
                "title": "Novo Nordisk’s Wegovy Pill Gets EU Panel Backing for Approval",
                "url": "https://finscans.com/news/novo-nordisks-wegovy-pill-gets-eu-panel-backing-for-approval"
            }
        }
    ]
}